- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 20.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works publishes Year-end report Q4 2025 | 5 | Cision News | ||
| 17.02. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Order from Returning Customer | 1 | Cision News | ||
| 19.01. | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 5 of 11 | 5 | Cision News | ||
| 02.01. | BIO-WORKS TECHNOLOGIES AB: Business Update | 1 | Cision News | ||
| 29.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Receives Two WorkBeads 100S and 100Q Orders Worth SEK 4 Million | 5 | Cision News | ||
| 15.12.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB Annual General Meeting to be held on Thursday 4 of June 2026 | 2 | Cision News | ||
| 07.11.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works reports third quarter 2025 | 1 | Cision News | ||
| BIO-WORKS TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 06.11.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads 40S from contract manufacturer in Europe | 3 | Cision News | ||
| 29.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works forms strategic partnership with Zenmindes Biotechnology to strengthen presence in China | 1 | Cision News | ||
| 21.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works two largest shareholders, members of the board and the CEO have all exercised all their Warrants TO2 | 1 | Cision News | ||
| 17.10.25 | BIO-WORKS TECHNOLOGIES AB: Correction: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 4 | Cision News | ||
| 17.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works receives order for WorkBeads affimAb valued at approximately SEK 8.3 million | 1 | Cision News | ||
| 16.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies AB announces outcome from exercise of warrants of series TO 2. Exercise period 4 of 11 | 1 | Cision News | ||
| 08.10.25 | BIO-WORKS TECHNOLOGIES AB: Strong interest in WorkBeads affimAb Edge: Next-Generation Protein A Resin for Antibody Purification | 3 | Cision News | ||
| 07.10.25 | BIO-WORKS TECHNOLOGIES AB: Bio-Works Technologies wins appeal against the Swedish Tax Agency in the Supreme Administrative Court | 2 | Cision News | ||
| 01.10.25 | BIO-WORKS TECHNOLOGIES AB: Today is the first day of the fourth exercise period for Bio-Works Technologies AB's warrants of series TO 2 | 1 | Cision News |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HELIX BIOPHARMA | 0,935 | +0,54 % | Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London | ||
| GALECTO | 30,020 | 0,00 % | Galecto, Inc.: Galecto Announces Acquisition of Damora Therapeutics | Acquisition of Damora and concurrent oversubscribed $285 million private investment positions the company to advance potentially best-in-class portfolio to improve outcomes in patients with Myeloproliferative... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 9,340 | 0,00 % | Vir Biotechnology +70%: Deal-Überraschung mit Ansage | Die Aktie von Vir Biotechnology ist vorbörslich um rund 70 Prozent nach oben geschossen. Auslöser der Kursexplosion ist vor allem ein milliardenschwerer Kooperationsdeal mit dem japanischen Pharmakonzern... ► Artikel lesen | |
| ARCELLX | 114,05 | +0,22 % | Weekly Buzz: MGNX's LINNET Trial On Hold; Eton Pharmaceuticals, ALUR Get FDA Nod; GILD Snaps Up ACLX | FOSTER CITY (dpa-AFX) - This week, the biotech space witnessed significant milestones, including FDA approvals, oncology drug acquisitions, and collaborations. Positive clinical trial results... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 90,10 | 0,00 % | Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress | ||
| BEAM THERAPEUTICS | 28,690 | +0,74 % | Beam Therapeutics Announces $500 Million Strategic Financing Facility with Sixth Street | $100 Million Funded at Close with up to an Additional $400 Million Available Under Facility with Seven-Year Term Financing Bolsters Balance Sheet with Long-term, Non-dilutive Capital to Support Anticipated... ► Artikel lesen | |
| QIAGEN | 41,295 | 0,00 % | Shortseller-Positionen aktuell: freenet, GFT, HelloFresh, Hypoport, Puma, Qiagen, Redcare Pharmacy | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,420 | -0,98 % | Vera Therapeutics, Inc. - 10-K, Annual Report | ||
| ARCUTIS BIOTHERAPEUTICS | 24,760 | -8,25 % | Arcutis Biotherapeutics, Inc.: Arcutis Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Q4 2025 net product revenue for ZORYVE (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product revenue for ZORYVE was... ► Artikel lesen | |
| ERASCA | 14,530 | +6,45 % | Erasca, Inc.: Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 | The issued patent provides intellectual property protection for ERAS-4001 and related compositions until at least 2043 Expands Erasca's diversified IP portfolio for RAS-driven cancers Initial Phase... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,630 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinical... ► Artikel lesen | |
| ADMA BIOLOGICS | 16,580 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| TREVI THERAPEUTICS | 12,570 | +5,54 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer | Experienced biotech CFO to lead financial strategy and contribute to the Company's next stage of growth
NEW HAVEN, Conn., Dec. 4, 2025 /PRNewswire/ -- Trevi Therapeutics... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 70,92 | +1,26 % | RBC Capital lowers Apogee Therapeutics stock price target on dosing outlook | ||
| PRAXIS PRECISION MEDICINES | 330,19 | -1,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen |
Das Unternehmen BIO-WORKS TECHNOLOGIES AB kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,245 Euro und damit -3,16 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIO-WORKS TECHNOLOGIES AB finden Sie auf Wallstreet Online.